

Part VI: Summary of the risk management plan

Summary of risk management plan for Dapagliflozin Accord 5 mg/ 10 mg film-coated tablets (Dapagliflozin)

This is a summary of the risk management plan (RMP) for Dapagliflozin Accord 5 mg/ 10 mg film-coated tablets. Throughout this summary, the product name is referred to as Dapagliflozin Accord. The RMP details important risks of Dapagliflozin Accord, how these risks can be minimised, and how more information will be obtained about Dapagliflozin Accord's risks and uncertainties (missing information).

Dapagliflozin Accord's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Dapagliflozin Accord should be used.

Important new concerns or changes to the current ones will be included in updates of Dapagliflozin Accord's RMP.

I. The medicine and what it is used for:

Dapagliflozin Accord is indicated for following indications:

Type 2 diabetes mellitus

Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.

Heart failure

Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.

Chronic kidney disease

Dapagliflozin is indicated in adults for the treatment of chronic kidney disease.

It contains Dapagliflozin as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks:

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorisation Holder

Important risks of Dapagliflozin Accord, together with measures to minimise such risks and the proposed studies for learning more about Dapagliflozin Accord's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Dapagliflozin is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information:

Important risks of Dapagliflozin Accord are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Dapagliflozin Accord. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Diabetic ketoacidosis including events with atypical presentation

Important potential risks	• Bladder cancer • Breast cancer • Prostate cancer
Missing information	• Use in patients with NYHA class IV • Long-term safety in the paediatric population (aged 10 years and above)

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan:**II.C.1 Studies which are conditions of the marketing authorisation:**

There are no studies which are conditions of the marketing authorisation or specific obligation of Dapagliflozin Accord.

II.C.2 Other studies in post-authorisation development plan:

There are no studies required for Dapagliflozin Accord.